Marginum is a Kuopio-based medtech company developing fluorescence-based tumour detection technology aimed at improving brain tumour care. The company’s core product is a fluorescence-guided detection system intended to help identify tumours during treatment. Recent reporting describes the technology as linked to a breakthrough therapy for brain tumour patients. Marginum raised €2.5M to expand and advance its detection technology toward patient use. The funding is presented as a step to bring the therapy closer to patients suffering from brain tumours. The article does not provide operating metrics, investor names, or details on prior financing rounds. Marginum Oy is a Finnish health startup based in Kuopio. The company has developed an invention that, if brought to market, could enable more precise cancer surgery. The article highlights the potential impact of the technology on surgical precision. Marginum has raised €1.7 million in financing. Investors in the round included venture capital firm Nostetta Ventures. The article does not report any operating metrics or additional financial details.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2025